- Active, not recruiting
NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hem. Malignancies (TTI-622-01)
Updated: Feb 10
NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies (TTI-622-01)
Sponsor
Trillium Therapeutics Inc.
Multicenter, open-label, phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in subjects with Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma.
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT02899052
Official Title: A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma
First Posted : May 21, 2018
PF-07901801 (TTI-622)
CD47-SIRPa Fusion Protein
SIRPa-IgG4-Fc Fusion Protein TTI-622 (Code C150756)
SIRPa-IgG4 Fc
SIRPa-IgG4 Fc TTI-622
SIRPa-IgG4-Fc Fusion Protein TTI-622
TTI 622
TTI-622
TTI622
Drug: TTI-622
Drug: Azacitidine
Drug: Venetoclax
Drug: Carfilzomib
Drug: Dexamethasone
Drug: anti-CD20 Targeting agent
3560 CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study
Program: Oral and Poster Abstracts Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III Hematology Disease Topics & Pathways: Clinical Trials, Biological, Lymphomas, Clinical Research, B Cell Lymphoma, T Cell Lymphoma, Diseases, Indolent Lymphoma, Aggressive Lymphoma, Therapies, Immunotherapy, Lymphoid Malignancies Monday, December 13, 2021, 6:00 PM-8:00 PM
Locations
United States, California
United States, Colorado
United States, District of Columbia
United States, Florida
United States, Georgia
United States, Kentucky
United States, Michigan
United States, New York
United States, Ohio
United States, Tennessee
United States, Texas
United States, Washington
Pfizer Completes Acquisition of Trillium Therapeutics